Eli Lilly and Company has announced a significant expansion of its U.S. manufacturing footprint, highlighted by the development of a new injectable medicine and device manufacturing facility in the Lehigh Valley, Pennsylvania. This multi-billion dollar investment is expected to create thousands of high-quality jobs and increase access to next-generation weight-loss treatments. The initiative is part of Lilly's broader commitment to invest over $50 billion in U.S. manufacturing since 2020, including new sites in Alabama, Pennsylvania, Texas, Virginia, North Carolina, and Indiana, as well as expansions in Puerto Rico and at the Lilly Technology Center in Indianapolis. The company has also acquired and expanded a manufacturing site in Wisconsin, underscoring its focus on innovation, workforce development, and domestic medicine supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE74818) on January 30, 2026, and is solely responsible for the information contained therein.